Synaptogenix (NASDAQ:TAOX) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Synaptogenix (NASDAQ:TAOX) from a hold rating to a sell rating in a research note released on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Synaptogenix Price Performance

Shares of TAOX stock opened at $3.90 on Friday. Synaptogenix has a one year low of $3.07 and a one year high of $10.00. The company’s fifty day moving average price is $3.67 and its 200-day moving average price is $4.38. The company has a market capitalization of $29.17 million, a price-to-earnings ratio of -1.01 and a beta of 1.49.

Synaptogenix (NASDAQ:TAOX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.83) earnings per share (EPS) for the quarter. The business had revenue of $0.09 million during the quarter. Synaptogenix had a negative return on equity of 128.51% and a negative net margin of 2,153.97%.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.